These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31029498)

  • 1. Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention.
    Caocci G; Mulas O; Bonifacio M; Abruzzese E; Galimberti S; Orlandi EM; Iurlo A; Annunziata M; Luciano L; Castagnetti F; Gozzini A; Stagno F; Binotto G; Pregno P; Albano F; Martino B; Fozza C; Scaffidi L; Trawinska MM; Baratè C; Elena C; Cattaneo D; Scalzulli E; La Nasa G; Foà R; Breccia M
    Int J Cardiol; 2019 Aug; 288():124-127. PubMed ID: 31029498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
    Caocci G; Mulas O; Abruzzese E; Luciano L; Iurlo A; Attolico I; Castagnetti F; Galimberti S; Sgherza N; Bonifacio M; Annunziata M; Gozzini A; Orlandi EM; Stagno F; Binotto G; Pregno P; Fozza C; Trawinska MM; De Gregorio F; Cattaneo D; Albano F; Gugliotta G; Baratè C; Scaffidi L; Elena C; Pirillo F; Scalzulli E; La Nasa G; Foà R; Breccia M
    Hematol Oncol; 2019 Aug; 37(3):296-302. PubMed ID: 30892724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
    Mulas O; Caocci G; Stagno F; Bonifacio M; Annunziata M; Luciano L; Orlandi EM; Abruzzese E; Sgherza N; Martino B; Albano F; Galimberti S; Pregno P; Bocchia M; Castagnetti F; Tiribelli M; Binotto G; Gozzini A; Capodanno I; Fozza C; Luzi D; Efficace F; Simula MP; Scaffidi L; De Gregorio F; Elena C; Trawinska MM; Cattaneo D; Attolico I; Baratè C; Pirillo F; Sicuranza A; Gugliotta G; Stella R; Scalzulli E; Iurlo A; Foà R; Breccia M; La Nasa G
    Ann Hematol; 2020 Jul; 99(7):1525-1530. PubMed ID: 32474619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee.
    Januzzi JL; Garasic JM; Kasner SE; McDonald V; Petrie MC; Seltzer J; Mauro M; Croce K; Berman E; Deininger M; Hochhaus A; Pinilla-Ibarz J; Nicolini F; Kim DW; DeAngelo DJ; Kantarjian H; Xu J; Hall T; Srivastava S; Naranjo D; Cortes J
    J Hematol Oncol; 2022 Jan; 15(1):1. PubMed ID: 34991679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors.
    Caocci G; Mulas O; Annunziata M; Luciano L; Abruzzese E; Bonifacio M; Orlandi EM; Albano F; Galimberti S; Iurlo A; Pregno P; Sgherza N; Martino B; Binotto G; Castagnetti F; Gozzini A; Bocchia M; Fozza C; Stagno F; Simula MP; De Gregorio F; Trawinska MM; Scaffidi L; Elena C; Attolico I; Baratè C; Cattaneo D; Pirillo F; Gugliotta G; Sicuranza A; Molica M; La Nasa G; Foà R; Breccia M
    Int J Cardiol; 2020 Feb; 301():163-166. PubMed ID: 31711851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of incidence/occurrence of cardiovascular events between ponatinib vs bosutinib among patients with at least one prior line of tyrosine kinase inhibitors in chronic myeloid leukemia in a community setting in the United States.
    Levy M; Xie L; Wang Y; Neumann F; Srivastava S; Naranjo D; Xu J; Zhang Q; Dalal M
    Cancer Treat Res Commun; 2021; 28():100424. PubMed ID: 34198039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.
    Caocci G; Mulas O; Capodanno I; Bonifacio M; Annunziata M; Galimberti S; Luciano L; Tiribelli M; Martino B; Castagnetti F; Binotto G; Pregno P; Stagno F; Abruzzese E; Bocchia M; Gozzini A; Albano F; Fozza C; Luzi D; Efficace F; Simula MP; Scaffidi L; Baratè C; De Gregorio F; Stella R; Gugliotta G; Pirillo F; Trawinska MM; Sicuranza A; Cattaneo D; Attolico I; Scalzulli E; Iurlo A; Foà R; Breccia M; La Nasa G
    Ann Hematol; 2021 Aug; 100(8):2005-2014. PubMed ID: 33388860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
    Mulas O; Abruzzese E; Luciano L; Iurlo A; Attolico I; Castagnetti F; Galimberti S; Bonifacio M; Annunziata M; Gozzini A; Orlandi EM; Stagno F; Binotto G; Pregno P; Fozza C; Loi M; Trawinska MM; De Gregorio F; Cattaneo D; Albano F; Iezza M; Baratè C; Scaffidi L; Elena C; Giai V; Scalzulli E; Breccia M; La Nasa G; Caocci G
    Ann Hematol; 2024 Feb; 103(2):427-436. PubMed ID: 38012435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Peripheral artery occlusive disease of the lower limbs: Rapid aggravation in a patient taking nilotinib for chronic myeloid leukemia].
    Gautier V; Mirault T; Azarine A; Alsac JM; Sapoval M; Réa D; Messas E
    J Mal Vasc; 2015 Jul; 40(4):231-9. PubMed ID: 26139550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis.
    Chai-Adisaksopha C; Lam W; Hillis C
    Leuk Lymphoma; 2016; 57(6):1300-10. PubMed ID: 26373533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
    Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
    Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Risk and Cardiovascular Events in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors.
    Assunção PM; Lana TP; Delamain MT; Duarte GO; Zulli R; Lorand-Metze I; de Souza CA; de Paula EV; Barbosa Pagnano KB
    Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):162-166. PubMed ID: 30660512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events.
    Abdelmagid MG; Al-Kali A; Litzow MR; Begna KH; Hogan WJ; Patnaik MS; Hashmi SK; Elliott MA; Alkhateeb H; Karrar OS; Fleti F; Elnayir MH; Rivera CE; Murthy HS; Foran JM; Kharfan-Dabaja MA; Badar T; Viswanatha DS; Reichard KK; Gangat N; Tefferi A
    Blood Cancer J; 2023 Aug; 13(1):122. PubMed ID: 37567878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors.
    Lipton JH; Bryden P; Sidhu MK; Huang H; McGarry LJ; Lustgarten S; Mealing S; Woods B; Whelan J; Hawkins N
    Leuk Res; 2015 Jan; 39(1):58-64. PubMed ID: 25466286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors.
    Nakazato T; Iriyama N; Tokuhira M; Ishikawa M; Sato E; Takaku T; Sugimoto KJ; Fujita H; Fujioka I; Kimura Y; Aisa Y; Iwanaga E; Asou N; Kizaki M; Hatta Y; Komatsu N; Kawaguchi T
    Med Oncol; 2018 May; 35(7):99. PubMed ID: 29846829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management of vascular adverse events during tyrosine kinase inhibitors in patients with chronic myeloid leukemia].
    Takaku T
    Rinsho Ketsueki; 2020; 61(9):1018-1027. PubMed ID: 33162495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.
    Valent P; Hadzijusufovic E; Schernthaner GH; Wolf D; Rea D; le Coutre P
    Blood; 2015 Feb; 125(6):901-6. PubMed ID: 25525119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial.
    Pulte ED; Chen H; Price LSL; Gudi R; Li H; Okusanya OO; Ma L; Rodriguez L; Vallejo J; Norsworthy KJ; de Claro RA; Theoret MR; Pazdur R
    Oncologist; 2022 Mar; 27(2):149-157. PubMed ID: 35641211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tyrosine kinase inhibitor-associated cardiovascular adverse events in chronic myeloid leukemia].
    Miyazaki S
    Rinsho Ketsueki; 2021; 62(8):1024-1028. PubMed ID: 34497188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.